Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

Francesco Fanfani; Gabriella Ferrandina; Giacomo Corrado; Anna Fagotti; Haim Vito Zakut; Salvatore Mancuso; Giovanni Scambia

doi:10.1159/000074644

Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

Francesco Fanfani, Gabriella Ferrandina, Giacomo Corrado, Anna Fagotti, Haim Vito Zakut, Salvatore Mancuso, Giovanni Scambia

Research output: Contribution to journal › Article

Abstract

Objectives: To report the results of neoadjuvant chemotherapy (NACT) and the impact of interval debulking surgery (IDS) on clinical outcomes of patients considered unresectable at primary surgery. Methods: Retrospective analysis was carried out on 73 consecutive stage IIIc ovarian cancer patients treated with platinum-based NACT followed by IDS. Their clinical outcomes were compared with those of 111 consecutive stage IIIc ovarian cancer patients treated with primary cytoreduction followed by platinum-based adjuvant chemotherapy. Results: Patients who underwent successful IDS had a more favorable prognosis than those who did not in terms of time to progression (TTP) (p = 0.00001), and overall survival (OS) (p = 0.0001). On the other hand, in the group of patients that underwent successful IDS, no differences in survival outcomes were observed between patients with no residual disease and patients with macroscopic residual disease

Original language	English
Pages (from-to)	316-322
Number of pages	7
Journal	Oncology
Volume	65
Issue number	4
DOIs	https://doi.org/10.1159/000074644
Publication status	Published - 2003

Fingerprint

Keywords

Advanced stage
Interval debulking surgery
Neoadjuvant chemotherapy
Ovarian cancer

ASJC Scopus subject areas

Cancer Research
Oncology

Cite this

Fanfani, F., Ferrandina, G., Corrado, G., Fagotti, A., Zakut, H. V., Mancuso, S., & Scambia, G. (2003). Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology, 65(4), 316-322. https://doi.org/10.1159/000074644

@article{9c84c5664fbd49fbb6e205344b17bc6a,

title = "Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients",

abstract = "Objectives: To report the results of neoadjuvant chemotherapy (NACT) and the impact of interval debulking surgery (IDS) on clinical outcomes of patients considered unresectable at primary surgery. Methods: Retrospective analysis was carried out on 73 consecutive stage IIIc ovarian cancer patients treated with platinum-based NACT followed by IDS. Their clinical outcomes were compared with those of 111 consecutive stage IIIc ovarian cancer patients treated with primary cytoreduction followed by platinum-based adjuvant chemotherapy. Results: Patients who underwent successful IDS had a more favorable prognosis than those who did not in terms of time to progression (TTP) (p = 0.00001), and overall survival (OS) (p = 0.0001). On the other hand, in the group of patients that underwent successful IDS, no differences in survival outcomes were observed between patients with no residual disease and patients with macroscopic residual disease ",

keywords = "Advanced stage, Interval debulking surgery, Neoadjuvant chemotherapy, Ovarian cancer",

author = "Francesco Fanfani and Gabriella Ferrandina and Giacomo Corrado and Anna Fagotti and Zakut, {Haim Vito} and Salvatore Mancuso and Giovanni Scambia",

year = "2003",

doi = "10.1159/000074644",

language = "English",

volume = "65",

pages = "316--322",

journal = "Oncology",

issn = "0030-2414",

publisher = "UBM Medica Healthcare Publications",

number = "4",

}

TY - JOUR

T1 - Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

AU - Fanfani, Francesco

AU - Ferrandina, Gabriella

AU - Corrado, Giacomo

AU - Fagotti, Anna

AU - Zakut, Haim Vito

AU - Mancuso, Salvatore

AU - Scambia, Giovanni

PY - 2003

Y1 - 2003

N2 - Objectives: To report the results of neoadjuvant chemotherapy (NACT) and the impact of interval debulking surgery (IDS) on clinical outcomes of patients considered unresectable at primary surgery. Methods: Retrospective analysis was carried out on 73 consecutive stage IIIc ovarian cancer patients treated with platinum-based NACT followed by IDS. Their clinical outcomes were compared with those of 111 consecutive stage IIIc ovarian cancer patients treated with primary cytoreduction followed by platinum-based adjuvant chemotherapy. Results: Patients who underwent successful IDS had a more favorable prognosis than those who did not in terms of time to progression (TTP) (p = 0.00001), and overall survival (OS) (p = 0.0001). On the other hand, in the group of patients that underwent successful IDS, no differences in survival outcomes were observed between patients with no residual disease and patients with macroscopic residual disease

AB - Objectives: To report the results of neoadjuvant chemotherapy (NACT) and the impact of interval debulking surgery (IDS) on clinical outcomes of patients considered unresectable at primary surgery. Methods: Retrospective analysis was carried out on 73 consecutive stage IIIc ovarian cancer patients treated with platinum-based NACT followed by IDS. Their clinical outcomes were compared with those of 111 consecutive stage IIIc ovarian cancer patients treated with primary cytoreduction followed by platinum-based adjuvant chemotherapy. Results: Patients who underwent successful IDS had a more favorable prognosis than those who did not in terms of time to progression (TTP) (p = 0.00001), and overall survival (OS) (p = 0.0001). On the other hand, in the group of patients that underwent successful IDS, no differences in survival outcomes were observed between patients with no residual disease and patients with macroscopic residual disease

KW - Advanced stage

KW - Interval debulking surgery

KW - Neoadjuvant chemotherapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0347319568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347319568&partnerID=8YFLogxK

U2 - 10.1159/000074644

DO - 10.1159/000074644

M3 - Article

C2 - 14707451

AN - SCOPUS:0347319568

VL - 65

SP - 316

EP - 322

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -

Access to Document

10.1159/000074644